PRO76 ITALIAN 648/96 LAW APPLICATION BETWEEN JAN 2013 AND MAY 2019: FOCUS ON ORPHAN DRUGS

On ‘focus movement’ in Italian

In this paper I discuss optional movement of focus constituents to the left periphery of the clause in Italian. Restricting my discussion to corrective exchanges – where focus occurs in a reply that denies the preceding assertion – I show that the fronted position and the ‘low’ position are not completely equivalent, in that certain contexts disallow the former, but allow the latter. I sketch o...

Rare diseases and orphan drugs.

According to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council, rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10 000 persons in the European Community. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare ...

Orphan drugs revisited.

Commentary Orphan drugs revisited

C. MCCABE, A. TSUCHIYA, K. CLAXTON and J. RAFTERY From the Section of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Department of Economics, University of Sheffield, Sheffield, Department of Economics and Related Studies, University of York, York, and Wessex Institute for Health Research and Development, University of Southampton, Southam...

Estimating the budget impact of orphan drugs in Sweden and France 2013–2020

BACKGROUND The growth in expenditure on orphan medicinal products (OMP) across Europe has been identified as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account for a significant proportion of total pharmaceutical expenditure in some countries, but few of these forecasts have been well validated. This analysis aims to establish a robust forecast of the fu...